ERBB2 and gastric cancer: Furthermore, previous in vitro studies demonstrated that trastuzumab in combination with DDP (14) and doxorubicin (15) produces a synergistic effect in human HER2-overexpressing GC cells; however, the mechanisms of this synergistic anticancer activity are yet to be fully explored.